anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Population aging longevity and advances in robotic surgery suggest that increasing numbers of older women having gynaeoncological surgery is likely. Postoperative morbidity and mortality are more common in older than younger women with the age-associated characteristics of multimorbidity and frailty being generally predictive of worse outcome. Priorities that inform treatment decisions change during the life course: older patients often place greater' value on quality-of-life-years gained than on life expectancy following cancer treatments. However, data on post-operative cognition, frailty, or functional independence is sparse and not routinely collected. This study aimed to describe the clinical characteristics and trajectory of functional change of older women in the 12 months following gynaeoncological surgery and to explore the associations between them.
MATERIALS AND METHODS: The prospective observational cohort study recruited consecutive women aged 65 or over scheduled for major gynaeoncologic surgery between July 2017 and April 2019. Baseline data on cancer stage, multimorbidity, and geriatric syndromes including cognition, frailty, and functional abilities were collected using standardised tools. Delirium and post-operative morbidity were recorded. Post hospital assessments were collected at 3-, 6-, and 12-months.
RESULTS: Overall, of 103 eligible participants assessed pre-operatively, most (77, 70%) remained independent in personal care at all assessments from discharge to 12 months. Functional trajectories varied widely over the 12 months but overall there was no significant decline or improvement for the 85 survivors. Eleven experienced a clinically significant decline in function at six months. This was associated with baseline low mood (P < 0.05), albeit with small numbers (6 of 11). Cognitive impairment and frailty were associated with lower baseline function but not with subsequent functional decline.
DISCUSSION: There was no clear clinical profile to identify the minority of older adults who experienced a clinically significant decline six months after surgery and for most, the decline was transient. This may be helpful in enabling informed patient consent. Assessment for geriatric syndromes and frailty may improve individual care but our findings do not indicate criteria for segmenting the patient population for selective attention. Future work should focus on causal pathways to potentially avoidable decline in those patients where this is not determined by the cancer itself.
INTRODUCTION AND AIMS: Posttransplantation diabetes mellitus (PTDM) is a serious long-term complication that has a negative impact on graft and patient survival. The purpose of the present study was to describe the incidence of PTDM in a Mexican cohort and evaluate its association with a previous family history of diabetes (FHD).
METHODS: A retrospective single-center cohort study was conducted on patients undergoing liver transplantation (LT). The primary outcome was time from LT to PTDM. The diagnosis of PTDM was established using the ADA criteria. A mediation analysis that used adjusted Cox regression models and considered pretransplant prediabetes a mediator was performed, to determine the total effect and direct effect of FHD on PTDM.
RESULTS: A total of 152 patients were included, with a median follow-up time of 41 months; 19.2% (n = 29) had pretransplant diabetes. During the follow-up time, 15% of patients developed PTDM (n = 23), with an incidence rate of 4.71 cases/100 person-years. PTDM was significantly higher in patients with FHD, compared with those with no FHD (8.72 cases/100 person-years vs 2.04 cases/100 person-years, respectively; p = 0.001). The adjusted hazard ratio of PTDM for FHD was 4.14 (95% CI 1.60-10.7), p = 0.005) and 3.48 (95% CI 1.35-9.01, p = 0.010), when further controlled for pretransplant prediabetes.
CONCLUSION: The occurrence of PTDM was similar to that reported in most international studies. As with type 2 diabetes, family history plays an important role in the development of PTDM, even after accounting for pretransplant prediabetes. Patients with FHD should undergo a stricter metabolic program.
The majority of people with Parkinson’s disease are 65 years and older. In Phase 3 clinical trials, the mean age of patients at study entry was 65 years. Of the total number of patients in clinical studies of GOCOVRI, 46% were less than 65 years of age, 39% were 65-74 years of age, and 15% were 75 years of age or older.

Hallucinations and falls occurred more frequently in patients 65 years of age or older, compared to those less than 65 years of age [see Adverse Reactions ( 6.1)]. 

No dose adjustment is recommended on the basis of age. GOCOVRI is known to be substantially excreted by the kidney, and the risk of adverse reactions may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [see Dosage and Administration ( 2.3)].
Use of an active ingredient (I) comprising combination of at least one active ingredient obtained from Medicago sativaand at least one active ingredient from Lupinus albus, for preparing a cosmetic and/or dermopharmaceutical composition for fighting against bags under the eyes, is claimed. An independent claim is included for preparing (I) comprising mixing the first primary active agent of Medicago sativawith the second primary active agent of Lupinus albus. ACTIVITY : Antiinflammatory; Dermatological. MECHANISM OF ACTION : Angiotensin converting enzyme inhibitor (ACE); Collagen I stimulator; Matrix metalloproteinase-1 inhibitor. The ability of (I) to inhibit the angiotensin converting enzyme was tested. The result showed that the percentage of inhibition of Medicago sativaand Lupinus albuswas 77%.
The Education arm is a chronic disease education program to teach patients how to live better with their chronic condition. It was developed by our research team to be specific for people with Parkinson's disease. It will include content and discussion of topics such as sleep, nutrition, and medication management. Classes will consist of a group of subjects (up to 6) meeting with the trainer for 90-minute session, once a week for six weeks. In order to match dose of the education intervention with the exercise intervention, participants will be provided relaxation tapes to be used at home 5 times per week for 30 minutes for an overall education dose of 240 minutes; similar to the exercise dose.
FIELD: medicine, sorbents. SUBSTANCE: invention relates to the use of food additions. Enterosorbent based on disintegrated wine yeast - Saccharomyces is used for removal of toxic metals from body. Enterosorbent is administrated by oral route at amount 0.08-0.14 g/kg patient body mass. EFFECT: enhanced effectiveness of a biosorbent. 2 cl, 1 tbl
The invention discloses a lurasidone HCl crystal A which is an orthorhombic system. A space group is P212121, cell parameters meet the equation of alpha = gamma = beta = 90.00 degrees. The unsymmetrical unit number Z in a cell is four. The crystal A can be a single crystal. The invention further discloses a purpose when the crystal A is used for preparing medicine for curing schizophrenia. Compared with existing lurasidone HCl, the lurasidone HCl crystal A has good solubility. Total related substances in the lurasidone HCl crystal A (high performance liquid chromatography (HPLC) detection) can be below 0.2%, single impurity is smaller than 0.1%, and high purity is achieved. Solvent with little toxicity is used during preparing, a production preparing process is safe, toxic substances with large toxicity cannot be left in obtained products, and the lurasidone HCl crystal A is suitable for officinal.
Ketoconazole has been shown to be teratogenic (syndactylia and oligodactylia) in the rat when given orally in the diet at 80 mg/kg/day, (10 times the maximum recommended human oral dose). However, these effects may be related to maternal toxicity, which was seen at this and higher dose levels.

There are no adequate and well-controlled studies in pregnant women. Ketoconazole should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers:It is not known whether Ketoconazole Cream 2% administered topically could result in sufficient systemic absorption to produce detectable quantities in breast milk. Nevertheless, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. 

Pediatric Use:Safety and effectiveness in children have not been established.
The invention provides an externally applied steam inhalation medicament for treating nasal polyps, and relates to the technical field of medicaments, in particular to an externally applied steam inhalation medicament for treating the nasal polyps. According to a formula, the medicament consists of the following components by weight: 2g of Chinese gall, 6g of atractylodes lancea, 6g of angelica dahurica, 3g of pulp of fructus mume, 2g of phellodendron, 2g of schisandra chinensis, 2g of siberian cocklour fruit and 2g of biond magnolia flower. The medicinal materials are crushed into coarse powder with particle diameter of about 30 to 50 meshes, and the coarse powder is put into a bubble bag made of filter paper, wherein each bag is about 27g. The coarse powder is inhaled into nasal cavities along with steam by fumigation, and fumigation lasts for 30 minutes every time. The medicament has effects of eliminating or reducing small polyps and preventing small polyps from relapsing; and the medicament has an effect of preventing the relapse of the large polyps of patients whose polyps is removed through operation. The medicament has the effects of removing blood stasis and eliminating lumps, clearing heat and removing toxicity, and eliminating polyps.
Anastomotic complications are serious complications after anus preserving surgery for rectal cancer, including anastomotic leakage, anastomotic bleeding, and anastomotic stenosis, with a incidence rate of 1.6% - 20.5% . The occurrence of anastomotic complications increases the perioperative mortality, hospital stay, and hospital costs of patients, and even some patients with severe anastomotic complications need to be re operated after surgery, which seriously affects the quality of life of patients. More research shows that , The complications of anastomotic stoma lead to the delay of postoperative adjuvant therapy, which increases the local recurrence rate of tumor. Therefore, how to reduce the occurrence of anastomotic complications in anus preserving surgery for rectal cancer has always been the focus of surgeons.

A variety of factors are involved in the occurrence of anastomotic complications after surgery, including gender, patient's general condition, tumor size and distance from anal margin, and instrument anastomosis technology . It is believed that , when using a closer to break the rectum during radical resection of rectal cancer, the use of multiple nail cages will increase the incidence of postoperative anastomotic complications. In the past, laparoscopic rectal cutting staplers were used in robotic radical resection of rectal cancer, and most of them were completed with the cooperation of assistants. In difficult cases, the mechanical arm needed to be removed and the main knife was used to perform rectal resection. In addition, the laparoscopic linear cutting closure device was cumbersome and complicated, and it often needed to use multiple nail silos to cut rectum in a narrow pelvic cavity, resulting in uneven anastomosis quality, Increase the occurrence of anastomotic complications. In recent years, the robot company has developed a new software driven robot assisted stapler (SureForm). The stapler can be directly loaded onto the mechanical arm. When the rectum is broken, the main knife can independently control it on the console. It has a joint head that rotates 60 ° from top to bottom, left to right, a 120 ° cone range of motion, and a 540 ° wrist joint design of the rod body, so that the stapler jaws can be vertically placed and separated from the rectum, The utility model can reduce the use of the nail bin when the rectum is transected, thereby reducing the incidence of postoperative anastomotic complications.

At present, only a few foreign studies have reported the application of robot linear cutting stapler SureForm in anus preserving surgery for rectal cancer, and the studies are retrospective, with a small sample size. There is no report in China. Therefore, this study adopts a prospective randomized controlled study method to evaluate the impact of robotic linear cutting stapler SureForm and laparoscopic linear cutting stapler on the incidence of anastomotic complications after robotic rectal cancer anus preserving surgery, so as to provide a reference for the application of robotic linear cutting stapler SureForm in robotic anus preserving surgery.
The invention relates to a traditional Chinese drug composition for treating carotid atherosclerosis plaque. The traditional Chinese drug composition comprises the following raw materials, wherein the raw materials comprise, by weight, 30-60 parts of mongolian milkvetch root, 12-26 parts of dangshen, 12-24 parts of angelica, 10-18 parts of szechwan lovage rhizome, 16-30 parts of rehmannia dride rhizome, 12-30 parts of dan-shen root, 12-18 parts of safflower, 20-60 parts of peach seed and 12-40 parts of lobed kudzuvine root. The traditional Chinese drug composition has advantages of scientific and reasonable formula, definite therapeutic effect, easy taking, and definite anti-arteriosclerosis therapeutic effect. With the traditional Chinese drug composition, the atherosclerotic plaque can be effectively eliminated so as to reduce the incidence and the re-admission rate of cardio-cerebrovascular important events. All the components of the traditional Chinese drug composition are the pure traditional Chinese drugs, no significant adverse reaction is generated, the safety is high, and the patient compliance is good. Compared to other drugs for treating the atherosclerosis, the traditional Chinese drug composition of the present invention has the following advantages that: the price is low, the traditional Chinese drug composition is easy to widely use in the community hospitals and the primary hospitals, such that the economic burden of the patient family and the society can be reduced, and the practicality is provided in the drug economics field.
Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) are commonly given to treat pediatric cancer, and carry a risk of cardiotoxicity. Over the long term, children who receive these therapies have an increased risk of heart failure and early cardiovascular death. However, current strategies for identifying patients who are at risk prior to the development of significant changes in heart function are limited. This study will focus on imaging markers of cardiac injury and dysfunction with the goal of developing improved diagnostic tests and treatment strategies.

Cardiac remodeling, function, and tissue characteristics will be examined using cardiac MRI data in combination with standard cardiac assessments (by echocardiography, electrocardiograms, and cardiac MRI) to assess the cardiotoxic effects of cancer therapy. Analyses will be performed in a cohort of adolescents and young adults with a history of childhood cancer.
The invention relates to an anesthesia method for carp, which belongs to the technical field of aquiculture. The invention is characterized in that the water of 99.98 to 99.99 weight percentage and the clove oil of 0.01 to 0.02 weight percentage are added in to a container to prepare anesthesia solution, and the carp is put into the container to be anesthetized. After being anesthetized for 2 to 5 minutes, the carp is found lying on side in the solution. And then, the carp is put into the waters of a pond. After 5 to 8 minutes, the crap can swim as usual. The anesthesia method of the invention adopts the clove oil that is commercially available and has good anesthesia effect. The clove oil can be used for soothing toothache of human. So the clove oil is safe to anesthetize the carp and does not affect edibleness. In addition, the clove oil has the advantages of low cost and wide application range.
This study will be designed as a prospective observational trial. After obtaining Institutional Review Board (IRB) approval, patients will be recruited and consented from the Anesthesia Pre-Operative Clinic. On the day of surgery, baseline urine samples will be obtained at the initial insertion of the Foley catheter, after induction of anesthesia. Urine samples will also be collected from the Foley catheter in the immediate post-operative period shortly after the patient is admitted to the Intensive Care Unit (ICU). Urine samples will continue to be collected for 72 hours post-operatively, at 0600 (6am) and 1800 (6pm) each day from the indwelling Foley catheter, which is standard of care in the ICU. Urine samples will be labeled and stored as per the instructions provided in a commercially available kit; six urine samples total will be collected and stored per patient. The electronic medical record (EMR) will be reviewed to determine whether the patient received ketorolac, ibuprofen, or no NSAIDs intra-operatively and postoperatively (within 72 hours of the beginning of surgery). Daily serum creatinine measurements and hourly urine output, which are standards of care in the ICU, will be obtained from the EMR as well.

AKI will be diagnosed and staged according to KDIGO criteria, which are based on changes in creatinine and urine output. In all patients with "KDIGO-diagnosed AKI" and in a matched non-AKI group, we will also compare the time course of new urinary biomarkers, including but not limited to uNGAL, to that of serum creatinine and urine output. We will match patients according to their demographics as well as clinical characteristics, including co-morbidities, type of surgery and anesthesia technique. Comparing the time course of current clinical markers (serum creatinine and urine output) with that of new urinary biomarkers will allow us to assess their role in guiding future preventive interventions.
Understanding cardiovascular control mediated by the autonomic system remains challenging due to its inherent complexity. Consequently, syndromes such as orthostatic intolerance continue to evoke debates regarding the underlying pathophysiological mechanisms. This study develops a comprehensive mathematical model simulating the control of the sympathetic branch of the cardiovascular system in individuals with normal and abnormal responses to the head-up-tilt test. We recruited four young women: one control, one with vasovagal syncope, one with orthostatic hypertension, and one with orthostatic hypotension, exposing them to an orthostatic head-up tilt test (HUTT) employing non-invasive methods to measure electrocardiography and continuous blood pressure. Our work encompasses a compartmental model formulated using a system of ordinary differential equations. Using heart rate as input, we predict blood pressure, flow, and volume in compartments representing the veins, arteries, heart, and the sympathetic branch of the baroreflex control system. The latter is modulated by high- and low-pressure baroreceptor afferents activated by changes in blood pressure induced by the HUTT. Sensitivity analysis, parameter subset selection, and optimization are employed to estimate patient-specific parameters associated with autonomic performance. The model has seven sensitive and identifiable parameters with significant physiological relevance that can serve as biomarkers for patient classification. Results show that the model can reproduce a spectrum of blood pressure responses successfully, fitting the trajectory displayed by the experimental data. The controller exhibits behavior that emulates the operation of the sympathetic system. These encouraging findings underscore the potential of computational methods in evaluating pathologies associated with autonomic nervous system control, warranting further exploration and novel approaches.
Patients initiated at 10 mg/day. After at least 8 weeks of treatment with a dose, optional up-titration to the next possible dose will be allowed. One down titration allowed from the highest dose attained.
UC arm: This is a prospective study for UC originated from the translational epithelium in the urinary tract (N=300). The study aims to obtain cancer tissues that originated from bladder (N=100), ureter (N=100), and renal pelvis (N=100).
A phytoestrogen supplement and methods of preparation are described. The basis of the oral phytoestrogen supplement was a preparation of the pomegranate material, preferably pomegranate seeds, which were contacted with an appropriate solvent as described below, preferably including water and ethanol. Preferably, the supplement also included an herbal mixture, including schizandra berries and Chinese asparagus root, and most preferably including Chinese licorice root and Chinese angelica root. The phytoestrogen supplement can also be prepared from pomegranate material alone without the addition of other herbals, which involves fermenting the pomegranate material including the pomegranate seeds. The basis of topical phytoestrogen supplements was a mixture of a preparation of the pomegranate material, preferably pomegranate seeds, which were pressed as described below to produce pomegranate oil, and of the coconut milk. Preferably, the supplements also included schizandra berries and Chinese asparagus root.
All subjects will receive Telaprevir twice a day, 1125mg capsule and Sofosbuvir 400 mg capsule once daily. Both will be given for 12 weeks.
Cross-sectional data collection for deliveries at the site. Data will be collected retrospectively from medical records for all women who deliver at the site (including the women enrolled in C1 above), as well from the medical records of all newborn infants and stillbirths delivered at the site. Missing or incomplete information in the woman or her infant's medical record will be clarified by contacting the woman to provide this information.
Prospective, open label study to assess the pharmacokinetics, safety \& efficacy of anidulafungin when used to treat children (aged 1 month - \< 18 years) with invasive candidiasis, including candidemia (ICC). To participate in the study, at the time of enrollment subjects must (1) have either a confirmed diagnosis of ICC or mycological evidence highly suggestive of Candida sp or (2) in infants 1 month to \< 2 years only, be at high risk of candidiasis. All subjects meeting screening criteria receive IV anidulafungin. Subjects will be stratified by age (1 month - \< 2 years; 2 years - \< 5 years; 5 years - \< 18 years). Subjects may be switched to oral fluconazole, provided that the pre-specified criteria are met. Subjects with microbiologically confirmed ICC must have a minimum total treatment duration of 14 days. The maximum allowed treatment duration of anidulafungin is 35 days; the maximum total treatment duration for the study is 49 days. At selected centers, anidulafungin pharmacokinetics will be assessed in the first 6 subjects age 1 month - \< 2 years to confirm the recommended dosage regimen. A population PK-PD analysis will be performed in all other enrolled subjects. Subjects will be followed for safety through 6 week FU visit. Efficacy for subjects with confirmed ICC will be assessed at EOIVT, EOT, 2-week FU and 6-week FU visits.